45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published: assessment threshold met
●Gross / standard charges: assessment threshold met
●Discounted cash price: assessment threshold met
●Payer-specific negotiated rates: assessment threshold met
○Min / max negotiated charges: below assessment threshold
●Free, public, no login required: assessment threshold met
Procedures listed
74,390
Insurances with rates
36
CPT / HCPCS codes
0
Most expensive procedures (gross)
ONC10326
$213,014
sipuleucel-T 50 million cells/250 mL Inj (ONC)
Gross
$355,023
ONC10326
$213,014
sipuleucel-T 50 million cells/250 mL Inj (ONC)
Gross
$355,023
ONC10386
$178,396
inebilizumab-cdon 100 mg/10 mL Inj (ONC)
Gross
$297,327
ONC10386
$178,396
inebilizumab-cdon 100 mg/10 mL Inj (ONC)
Gross
$297,327
ONC10367
$157,933
tremelimumab-actl 300 mg/15 mL Inj (ONC)
Gross
$263,222
ONC10367
$157,933
tremelimumab-actl 300 mg/15 mL Inj (ONC)
Gross
$263,222
ONC10192
$138,211
ipilimumab 200 mg/40 mL Inj (ONC)
Gross
$230,352
ONC10192
$138,211
ipilimumab 200 mg/40 mL Inj (ONC)
Gross
$230,352
PHD64823
$119,668
glucarpidase 1000 units
Gross
$199,446
PHD64823
$119,668
glucarpidase 1000 units
Gross
$199,446
ONC10146
$117,315
pegloticase 8 mg/1 mL Inj (ONC)
Gross
$195,525
ONC10146
$117,315
pegloticase 8 mg/1 mL Inj (ONC)
Gross
$195,525
ONC10234
$108,076
loncastuximab tesirine 10 mg Inj (ONC)
Gross
$180,126
ONC10234
$108,076
loncastuximab tesirine 10 mg Inj (ONC)
Gross
$180,126
54860-2869452
$96,637
Y-90 Zevalin, Per Dose
Gross
$161,062
54860-2869452
$96,637
Y-90 Zevalin, Per Dose
Gross
$161,062
ONC10140
$91,397
ravulizumab-cwvz 1100 mg/11 mL Inj (ONC)
Gross
$152,328
ONC10140
$91,397
ravulizumab-cwvz 1100 mg/11 mL Inj (ONC)
Gross
$152,328
ONC10324
$84,851
inotuzumab ozogamicin 0.9 mg Inj (ONC)
Gross
$141,418
ONC10324
$84,851
inotuzumab ozogamicin 0.9 mg Inj (ONC)
Gross
$141,418
PHD64949
$84,533
ravulizumab-cwvz 1100 mg/11 mL Inj
Gross
$140,888
PHD64949
$84,533
ravulizumab-cwvz 1100 mg/11 mL Inj
Gross
$140,888
PHD64928
$78,865
inotuzumab ozogamicin 0.9 mg Inj
Gross
$131,441
PHD64928
$78,865
inotuzumab ozogamicin 0.9 mg Inj
Gross
$131,441
ONC10115
$78,766
ocrelizumab 300 mg/10 mL Inj (ONC)
Gross
$131,277
ONC10115
$78,766
ocrelizumab 300 mg/10 mL Inj (ONC)
Gross
$131,277
PHD64221
$74,307
ocrelizumab 300 mg/10 mL Inj
Gross
$123,846
PHD64221
$74,307
ocrelizumab 300 mg/10 mL Inj
Gross
$123,846
ONC10390
$71,741
linvoseltamab-gcpt 200 mg/10 mL Inj (ONC)
Gross
$119,568
ONC10390
$71,741
linvoseltamab-gcpt 200 mg/10 mL Inj (ONC)
Gross
$119,568
ONC10292
$71,588
tebentafusp tebn 100 mcg/0.5 mL Inj (ONC)
Gross
$119,314
ONC10292
$71,588
tebentafusp tebn 100 mcg/0.5 mL Inj (ONC)
Gross
$119,314
ONC10212
$71,021
polatuzumab vedotin 140 mg Inj (ONC)
Gross
$118,369
ONC10212
$71,021
polatuzumab vedotin 140 mg Inj (ONC)
Gross
$118,369
PHD64129
$68,490
fluocinolone Opth 0.59 mg implant
Gross
$114,150
PHD64129
$68,490
fluocinolone Opth 0.59 mg implant
Gross
$114,150
PHD65091
$67,001
polatuzumab vedotin 140 mg Inj
Gross
$111,668
PHD65091
$67,001
polatuzumab vedotin 140 mg Inj
Gross
$111,668
ONC10301
$62,889
epcoritamab 48 mg/0.8 mL Inj (ONC)
Gross
$104,815
ONC10301
$62,889
epcoritamab 48 mg/0.8 mL Inj (ONC)
Gross
$104,815
7081868-2869452
$59,312
Provenge 1 Unit
Gross
$98,853
7081868-2869452
$59,312
Provenge 1 Unit
Gross
$98,853
ONC10323
$58,850
nivolumab-relatlimab rmbw 240 mg-80 mg/20 mL Inj (
Gross
$98,084
ONC10323
$58,850
nivolumab-relatlimab rmbw 240 mg-80 mg/20 mL Inj (
Gross
$98,084
ONC10377
$57,240
tarlatamab-dlle 10 mg Inj (ONC)
Gross
$95,400
ONC10377
$57,240
tarlatamab-dlle 10 mg Inj (ONC)
Gross
$95,400
PHD64927
$56,783
efgartigimod alfa-hyaluronidase qvfc 180 mg-2000 u
Gross
$94,638
PHD64927
$56,783
efgartigimod alfa-hyaluronidase qvfc 180 mg-2000 u
Gross
$94,638
ONC10380
$56,259
retifanlimab-dlwr 500 mg/20 mL Inj (ONC)
Gross
$93,765
ONC10380
$56,259
retifanlimab-dlwr 500 mg/20 mL Inj (ONC)
Gross
$93,765
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| ONC10326 | sipuleucel-T 50 million cells/250 mL Inj (ONC) | $355,023 | $213,014 | — | — | 10 |
| ONC10326 | sipuleucel-T 50 million cells/250 mL Inj (ONC) | $355,023 | $213,014 | — | — | 11 |
| ONC10386 | inebilizumab-cdon 100 mg/10 mL Inj (ONC) | $297,327 | $178,396 | — | — | 10 |
| ONC10386 | inebilizumab-cdon 100 mg/10 mL Inj (ONC) | $297,327 | $178,396 | — | — | 11 |
| ONC10367 | tremelimumab-actl 300 mg/15 mL Inj (ONC) | $263,222 | $157,933 | — | — | 10 |
| ONC10367 | tremelimumab-actl 300 mg/15 mL Inj (ONC) | $263,222 | $157,933 | — | — | 11 |
| ONC10192 | ipilimumab 200 mg/40 mL Inj (ONC) | $230,352 | $138,211 | — | — | 10 |
| ONC10192 | ipilimumab 200 mg/40 mL Inj (ONC) | $230,352 | $138,211 | — | — | 11 |
| PHD64823 | glucarpidase 1000 units | $199,446 | $119,668 | — | — | 10 |
| PHD64823 | glucarpidase 1000 units | $199,446 | $119,668 | — | — | 10 |
| ONC10146 | pegloticase 8 mg/1 mL Inj (ONC) | $195,525 | $117,315 | — | — | 10 |
| ONC10146 | pegloticase 8 mg/1 mL Inj (ONC) | $195,525 | $117,315 | — | — | 11 |
| ONC10234 | loncastuximab tesirine 10 mg Inj (ONC) | $180,126 | $108,076 | — | — | 10 |
| ONC10234 | loncastuximab tesirine 10 mg Inj (ONC) | $180,126 | $108,076 | — | — | 11 |
| 54860-2869452 | Y-90 Zevalin, Per Dose | $161,062 | $96,637 | — | — | 10 |
| 54860-2869452 | Y-90 Zevalin, Per Dose | $161,062 | $96,637 | — | — | 11 |
| ONC10140 | ravulizumab-cwvz 1100 mg/11 mL Inj (ONC) | $152,328 | $91,397 | — | — | 10 |
| ONC10140 | ravulizumab-cwvz 1100 mg/11 mL Inj (ONC) | $152,328 | $91,397 | — | — | 11 |
| ONC10324 | inotuzumab ozogamicin 0.9 mg Inj (ONC) | $141,418 | $84,851 | — | — | 10 |
| ONC10324 | inotuzumab ozogamicin 0.9 mg Inj (ONC) | $141,418 | $84,851 | — | — | 11 |
| PHD64949 | ravulizumab-cwvz 1100 mg/11 mL Inj | $140,888 | $84,533 | — | — | 10 |
| PHD64949 | ravulizumab-cwvz 1100 mg/11 mL Inj | $140,888 | $84,533 | — | — | 11 |
| PHD64928 | inotuzumab ozogamicin 0.9 mg Inj | $131,441 | $78,865 | — | — | 10 |
| PHD64928 | inotuzumab ozogamicin 0.9 mg Inj | $131,441 | $78,865 | — | — | 11 |
| ONC10115 | ocrelizumab 300 mg/10 mL Inj (ONC) | $131,277 | $78,766 | — | — | 10 |
| ONC10115 | ocrelizumab 300 mg/10 mL Inj (ONC) | $131,277 | $78,766 | — | — | 11 |
| PHD64221 | ocrelizumab 300 mg/10 mL Inj | $123,846 | $74,307 | — | — | 10 |
| PHD64221 | ocrelizumab 300 mg/10 mL Inj | $123,846 | $74,307 | — | — | 11 |
| ONC10390 | linvoseltamab-gcpt 200 mg/10 mL Inj (ONC) | $119,568 | $71,741 | — | — | 6 |
| ONC10390 | linvoseltamab-gcpt 200 mg/10 mL Inj (ONC) | $119,568 | $71,741 | — | — | 9 |
| ONC10292 | tebentafusp tebn 100 mcg/0.5 mL Inj (ONC) | $119,314 | $71,588 | — | — | 10 |
| ONC10292 | tebentafusp tebn 100 mcg/0.5 mL Inj (ONC) | $119,314 | $71,588 | — | — | 11 |
| ONC10212 | polatuzumab vedotin 140 mg Inj (ONC) | $118,369 | $71,021 | — | — | 10 |
| ONC10212 | polatuzumab vedotin 140 mg Inj (ONC) | $118,369 | $71,021 | — | — | 11 |
| PHD64129 | fluocinolone Opth 0.59 mg implant | $114,150 | $68,490 | — | — | 10 |
| PHD64129 | fluocinolone Opth 0.59 mg implant | $114,150 | $68,490 | — | — | 11 |
| PHD65091 | polatuzumab vedotin 140 mg Inj | $111,668 | $67,001 | — | — | 10 |
| PHD65091 | polatuzumab vedotin 140 mg Inj | $111,668 | $67,001 | — | — | 11 |
| ONC10301 | epcoritamab 48 mg/0.8 mL Inj (ONC) | $104,815 | $62,889 | — | — | 6 |
| ONC10301 | epcoritamab 48 mg/0.8 mL Inj (ONC) | $104,815 | $62,889 | — | — | 9 |
| 7081868-2869452 | Provenge 1 Unit | $98,853 | $59,312 | — | — | 10 |
| 7081868-2869452 | Provenge 1 Unit | $98,853 | $59,312 | — | — | 11 |
| ONC10323 | nivolumab-relatlimab rmbw 240 mg-80 mg/20 mL Inj ( | $98,084 | $58,850 | — | — | 10 |
| ONC10323 | nivolumab-relatlimab rmbw 240 mg-80 mg/20 mL Inj ( | $98,084 | $58,850 | — | — | 11 |
| ONC10377 | tarlatamab-dlle 10 mg Inj (ONC) | $95,400 | $57,240 | — | — | 9 |
| ONC10377 | tarlatamab-dlle 10 mg Inj (ONC) | $95,400 | $57,240 | — | — | 11 |
| PHD64927 | efgartigimod alfa-hyaluronidase qvfc 180 mg-2000 u | $94,638 | $56,783 | — | — | 10 |
| PHD64927 | efgartigimod alfa-hyaluronidase qvfc 180 mg-2000 u | $94,638 | $56,783 | — | — | 11 |
| ONC10380 | retifanlimab-dlwr 500 mg/20 mL Inj (ONC) | $93,765 | $56,259 | — | — | 10 |
| ONC10380 | retifanlimab-dlwr 500 mg/20 mL Inj (ONC) | $93,765 | $56,259 | — | — | 11 |
Showing top 50 of 74,390 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.